Search the Newsreel

StemPoint Capital reports 5.0% Surrozen (SRZN) stake via shares and warrants

StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross have collectively reported a beneficial ownership of 5.0% in Surrozen, Inc. (SRZN). This stake includes 273,140 shares of common stock and 329,658 shares issuable upon exercise of Series A, B, and E warrants, …

Analysts Just Made A Massive Upgrade To Their Surrozen, Inc. (NASDAQ:SRZN) Forecasts

Analysts have significantly upgraded their near-term forecasts for Surrozen, Inc. (NASDAQ:SRZN), projecting greatly increased statutory revenues and earnings per share for 2026. While revenue is still expected to decline compared to past performance and lag the wider industry, analysts have reduced their loss estimates …

What is HC Wainwright's Estimate for Surrozen Q3 Earnings?

HC Wainwright has revised its Q3 2026 EPS estimate for Surrozen to a loss of $1.33 per share, down from $1.19, while maintaining a "Buy" rating and a $44 price target. Despite the lowered estimate, Surrozen's recent Q2 results significantly surpassed expectations, reporting a …

Surrozen (SRZN): 5AM Ventures group reports 7.8% beneficial ownership stake

5AM Ventures group, including 5AM Ventures VII, L.P., 5AM Partners VII, LLC, Kush Parmar, and Andrew J. Schwab, has reported a beneficial ownership stake of 7.8% in Surrozen, Inc. (SRZN), totaling 968,750 shares as of June 30, 2026. This includes currently held shares and …

H.C. Wainwright reiterates Surrozen stock rating at buy, $44 target

H.C. Wainwright has reiterated a buy rating and a $44 price target for Surrozen Inc. (NASDAQ:SRZN) shares, following a significant 168% gain over the past year. The firm is encouraged by the detailed clinical steps for SZN-8141, a lead bifunctional Wnt/anti-VEGF antibody, which is …

Surrozen Inc (SRZN) Earnings Forecast: Future EPS & Revenue Growth Estimates

Surrozen Inc (SRZN) has an earnings forecast score of 8.40, placing it 132nd in the Biotechnology & Medical Research industry. Analysts have an average price target of $37.00 for SRZN, with a "Buy" trend based on 5 analysts. The company's expected revenue for the …

Surrozen (SRZN) warrants expiring 2026 removed from Nasdaq listing

Surrozen, Inc. (SRZN) warrants expiring on August 10, 2026, have been delisted from the Nasdaq Stock Market LLC. This removal was processed under Section 12(b) of the Securities Exchange Act of 1934, following Nasdaq's and SEC's rules. The delisting signifies that the warrants will …

Surrozen (NASDAQ:SRZN) Issues Quarterly Earnings Results, Beats Expectations By $0.88 EPS

Surrozen (NASDAQ:SRZN) announced its quarterly earnings, reporting an EPS loss of $0.41, significantly better than the consensus estimate of ($1.29), and revenue of $5.00 million, surpassing expectations. Despite beating earnings, the stock declined by $0.31 to $21.64. Analysts maintain a "Moderate Buy" rating, but …

Surrozen, Inc. 2Q 2026: Revenue $5M, Net income $50.18M, EPS $(0.41) — 10-Q Summary

Surrozen, Inc. reported its second-quarter 2026 results, showing a significant increase in revenue to $5M, up 408% year-over-year, and net income of $50.18M. This growth was primarily driven by collaboration milestone recognition and noncash fair value gains. The company also highlighted pipeline progress with …

Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update

Surrozen, Inc. (Nasdaq: SRZN) announced its financial results for the second quarter ended June 30, 2026, and provided a business update. The company plans to submit an IND application for SZN-8141 for diabetic macular edema (DME) by the end of Q3 2026 and initiate …

Surrozen (NASDAQ: SRZN) swings to $50.2M profit on Boehringer milestone revenue

Why (SRZN) Price Action Is Critical for Tactical Trading

This article analyzes Surrozen Inc. (NASDAQ: SRZN) focusing on its price action for tactical trading. It highlights mixed sentiment across different timeframes, with positive near-term sentiment potentially eroding a mid-term weak bias within a long-term strong context. The analysis also provides AI-generated institutional trading …

Price to earnings forward of Surrozen, Inc. – BOATS:SRZNW

This article provides financial information for Surrozen, Inc. (SRZNW) on TradingView, specifically focusing on its price to earnings forward. It indicates that the market is closed with no recent trades for the company.

Price to sales forward of Surrozen, Inc. – BOATS:SRZNW

This article focuses on the "Price to sales forward" metric for Surrozen, Inc. (SRZNW) on the Blue Ocean Alternative Trade System (BOATS). It provides a snapshot of this financial ratio, indicating its current value and change percentage. The content is presented within the TradingView …

Surrozen Inc (SRZN) Institutional Confidence

Surrozen Inc (SRZN) has an institutional shareholding score of 10.00, placing it first in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 94.38%, showing an 11.10% increase quarter-over-quarter. James Simons is the largest institutional shareholder, holding 0.43% of outstanding shares.

Surrozen Inc (SRZN) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Surrozen Inc (SRZN), detailing its current price momentum, support and resistance levels, and various technical indicators and moving averages. The stock currently ranks 115 out of 385 in the Biotechnology & Medical Research industry with a price …

Surrozen Inc (SRZN) Financial Health: Profitability & Balance Sheet Analysis

Surrozen Inc (SRZN) has an improved financial score of 8.27, ranking 53rd in the Biotechnology & Medical Research industry, indicating stable financial health and high operating efficiency. The company reported a significant year-over-year revenue increase of 408.65% to $5.00M and a net profit increase …

Surrozen Inc (SRZN) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Surrozen Inc (SRZN), detailing its volatility, financial risk, and investment risk. It highlights the company's current risk assessment score of 2.53, ranking it among its industry peers, and notes its beta value of 0.52. The report also …

Surrozen, Inc. Revenue Breakdown – NASDAQ:SRZN

Surrozen, Inc. (NASDAQ: SRZN) generated $3.48 million USD in revenue last year, primarily from its Research Service Revenue - Related Party segment. This segment matched the total company revenue, indicating its sole contribution to the company's earnings. The United States was the exclusive geographic …

Surrozen Inc (SRZN) Valuation: PE, PB & Fair Value Analysis

The article provides a valuation analysis for Surrozen Inc (SRZN), noting its current valuation score is 8.29, ranking 150 out of 386 in its industry. It highlights the company's P/E ratio of -0.54 and mentions that relevant data for P/B, P/S, and P/CF ratios …

SRZN|Surrozen Inc|Price:19.660|Chg%:-0.070

This article provides a comprehensive stock analysis of Surrozen Inc (SRZN), highlighting its "fairly valued" status and strong fundamentals despite recent market performance. The company, a biotechnology firm focused on the Wnt pathway, shows high institutional ownership and analyst ratings predominantly as "Buy." It …

Surrozen Inc (SRZN) Cash Flow

This article provides a detailed overview of Surrozen Inc's (SRZN) cash flow statement, including quarterly and annual figures for operating, investing, and financing activities. It presents financial data such as net income, capital expenditures, and free cash flow over several fiscal quarters and years. …

Surrozen Inc (SRZN) Income Statement

TCG Crossover GP II sells $6.9 million in Surrozen shares

TCG Crossover GP II, a significant shareholder and director in Surrozen, Inc. (NASDAQ:SRZN), sold 325,000 shares of the company's common stock for approximately $6.9 million on July 22, 2026. This sale, executed at $21.25 per share, followed the reporting persons disgorging short-swing profits as …

Surrozen (SRZN): TCG Crossover funds, Chen Yu disclose 9.9% stake

An amended ownership report for Surrozen, Inc. (SRZN) filed by investment entities TCG Crossover and Chen Yu shows that Chen Yu beneficially owns 1,148,101 shares, representing 9.9% of the common stock. TCG Crossover Fund II, L.P. and TCG Crossover GP II, LLC each report …

Form 4 Surrozen Inc For: 24 July By Investing.com

This article reports on a Form 4 filing for Surrozen Inc. on July 24, indicating insider trading activity. The stock symbol SRZN is noted with a -6.76% change. The content primarily lists market data and unrelated news, with the Form 4 information being brief.

SRZN|Surrozen Inc|Price:21.170|Chg%:-0.550

Surrozen Inc (SRZN) is a biotechnology company developing drug candidates to modulate the Wnt pathway, with a focus on ophthalmology. The company shows strong fundamentals, high growth potential, and institutional buying, despite a recent sideway trading pattern. Analysts have an average "Buy" rating with …

Understanding Momentum Shifts in (SRZN)

This article provides an AI-generated analysis of Surrozen Inc. (NASDAQ: SRZN), highlighting shifting sentiment from positive near-term to potential mid-term weakness within a long-term strong outlook. It presents three institutional trading strategies tailored for different risk profiles, including position trading, momentum breakout, and risk …

Surrozen Highlights Wnt Retina Pipeline, SZN-8141 IND Timeline at H.C. Wainwright

Surrozen highlighted its Wnt-based retina strategy at H.C. Wainwright's conference, emphasizing the potential of its Frizzled-4 signaling therapies for retinal vascular diseases. The company's lead preclinical program, SZN-8141, combines Wnt agonism and VEGF inhibition, showing promising synergy in preclinical models and targeting an IND …

Surrozen's Insider Selling: A $7 Million Red Flag Amidst Biotech Optimism

A $6.9 million insider stock sale by TCG Crossover GP II, LLC, a 10% owner of Surrozen (NASDAQ: SRZN), on July 22, 2026, has raised concerns despite being compliance-driven due to "short-swing profits." This transaction challenges prior narratives of strong institutional confidence in the …

Surrozen Inc. (SRZN) Gains 3.75% as Shares Approach Key Resistance at $24.14 - PCR Spike

Surrozen to Present at Upcoming Healthcare Investor Conference

Surrozen, Inc. announced that its management will present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference on July 22, 2026. Interested parties can access an audio webcast of the fireside chat, which will be available on Surrozen's investor relations website. The company is …

SRZN Q1 2026 Earnings: Wider-than-Expected Loss Amid Clinical Progress - Next Quarter Guidance